KCNH2 and cancer: scDb-hERG1-β1-TRAIL showed a good penetration into cancer tissues in vivo, hence overcoming one of the hindrances (low delivery and nonhomogeneous distribution) for TRAIL linked to full-length antibodies (46, 47), as well as no toxicity to the heart, kidney, and liver.